Noxopharm (ASX:NOX) said US-based Tezcat Biosciences found "encouraging" results in its pre-clinical in vitro studies of assets from the Sofra technology platform, according to a Tuesday filing with the Australian bourse.

Tezcat Biosciences conducted a series of studies, which demonstrated that the company's oligonucleotides can be attached to Tezcat's delivery system to create a new drug candidate with strong anti-inflammatory activity, the filing said.

The company has partnered with Tezcat since 2024, and plans are underway to undertake further studies in animal models, per the filing.

Noxopharm shares rose 9% in afternoon trade on Tuesday.